[{"orgOrder":0,"company":"Vivozon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Opiranserin Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Vivozon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vivozon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivozon \/ Inapplicable"},{"orgOrder":0,"company":"Vivozon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"14-C VVZ-149","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Vivozon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vivozon \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivozon \/ Inapplicable"},{"orgOrder":0,"company":"Vivozon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VVZ-149","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vivozon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vivozon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vivozon \/ Inapplicable"},{"orgOrder":0,"company":"Vivozon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VVZ-149","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vivozon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vivozon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vivozon \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Vivozon

Vivozon
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

02

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

03

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

04

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

05

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

06

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

07

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

08

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

09

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

10

Vivozon

South Korea

World Drug Safety EU

Not Confirmed

1
2